Selank over time

Gene expression at one and three hours

The 2016 rat frontal-cortex study counted significant changes in expression of 45 genes at one hour and 22 at three hours. The shifts correlated positively with those produced by GABA itself. GABA is an inhibitory messenger in the nervous system; changing a gene associated with its signalling is several steps removed from measuring a person’s anxiety.

I can’t see a duration of action hiding in that smaller later count. The reported counts describe altered expression at those sampling times. They don’t provide a human duration of action, and they don’t establish that each gene moved in the same direction. The experiment is more useful when its hours stay attached to its measurements.

What it is

Selank's parent sequence is tuftsin — Thr-Lys-Pro-Arg — an endogenous tetrapeptide released by enzymatic cleavage of the heavy chain of immunoglobulin G. Tuftsin is classically described as an immunostimulant: it activates macrophages and monocytes, promotes phagocytosis, and modulates cytokine release. Because tuftsin is rapidly degraded by plasma and tissue enzymes (half-life is seconds to minutes), researchers at the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology in Moscow added the C-terminal extension Pro-Gly-Pro to create a metabolically more stable analogue.

The result is Selank (TP-7, sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro), a molecule that retains tuftsin's immunomodulatory properties while gaining measurable stability and additional CNS activity not seen with the parent tetrapeptide. The Pro-Gly-Pro tail is the same sequence found in some neuropeptide degradation products (including collagen-derived fragments), which may contribute to its central effects. It is a fully synthetic research compound, not a natural product extractable from any tissue.

The evidence for Selank remains a separate question from care: Promise Peptides (mypromise.com) currently prescribes Semax/Selank in one blended formulation as prescription-only medication through clinicians licensed in the U.S. Every request goes to a provider for assessment and a prescribing decision. Some patients will not qualify. Care is limited to U.S. patients, with options depending on the state and treatment. The medications are compounded and have no FDA approval.

Receptor binding and peptide breakdown

The 2018 molecular review describes concentration-dependent, subtype-selective modulation of GABA binding in rat brain membrane experiments. “Allosteric” means acting at a different binding site from the main messenger. The same review reports interference with the modulatory activity of diazepam and olanzapine. That makes a blanket promise of predictable interactions hard to defend.

Another experiment gives duration a chemical meaning: Selank slowed the breakdown of enkephalins in human plasma in vitro. Enkephalins are the body’s own opioid peptides. The authors proposed that preserving them could help explain an anxiety effect. I trust the enkephalin assay to describe what happened in the plasma: slowing degradation in a plasma assay is a concrete observation, while its consequences inside a living human nervous system still need demonstrating.

Anxiety studies in people

A 2008 Russian clinical study in patients with generalized anxiety disorder reported an anxiolytic effect comparable to a benzodiazepine comparator, with mild activation and without sedation, cognitive impairment or withdrawal on stopping. This is an encouraging short-term report from a narrow clinical literature, with limited independent Western replication and no established long-term safety record.

I rate the Selank patient outcomes above a receptor nickname, with follow-up deciding how much weight they earn. A favourable account over a few weeks cannot settle what repeated exposure does over a much longer period.

In patients with anxiety-asthenic disorders, immune assays also found changes in Th1/Th2 cytokine balance and IL-6 expression. The immune findings widen the questions about longer exposure, particularly when immune conditions or medications are involved. They do not demonstrate harm in those groups.

BDNF and stress experiments in rats

The rat hippocampus study reported increased BDNF expression after intranasal Selank. BDNF is a signal involved in neuronal survival and plasticity. A change in that signal can motivate a memory experiment; it does not measure a human improvement in memory or focus.

There is also a rat chronic-stress experiment in which Selank with diazepam reduced anxiety-related behaviour most effectively among the tested conditions. I read Selank’s diazepam comparison as an interaction question for people. It supplies no human combination protocol, whether with diazepam or with DSIP.

Selank tolerability

Selank anecdotes often describe less background anxiety with mental clarity preserved. Others describe little effect, drowsiness or feeling over-calm; nasal irritation and occasional headache also appear. These are informal accounts, not clinical evidence, and they cannot establish how often an effect occurs or what caused it. Reports of no rebound or dependence remain short-term anecdotes rather than a long-term safety record.

The clinical literature leaves long-term safety and medication interactions poorly characterized. Its activity across GABA binding, enkephalin breakdown and immune signalling gives several reasons for caution. Pregnancy, breastfeeding and significant pre-existing conditions lack human safety data.

Selank has no FDA or EMA approval; its anxiolytic registration is essentially confined to Russia. Research-only material is not intended for human consumption, and its identity, purity and sterility are separate uncertainties. Clinical assessment of persistent anxiety matters more than the appealing idea of a non-sedating peptide.